Biological therapy of severe asthma- Position of Polish Society of Allergology and Polish Society of Respiratory Diseases

被引：1
作者：
Rogala, Barbara [1 ,9 ]
Kupczyk, Maciej [2 ]
Bochenek, Grazyna [3 ]
Sliwinski, Pawel [4 ]
Moniuszko, Marcin [5 ]
Kuna, Piotr [2 ]
Gluck, Joanna [1 ]
Dobek, Rafal [4 ]
Kulus, Marek [6 ]
Kucharczyk, Aleksandra [7 ]
Chalubinski, Maciej [8 ]
机构：
[1] Slaski Uniwersytet Med Katowicach, Uniwersyteckie Ctr Klin, Katowice, Poland
[2] Uniwersytet Med Lodzi, Klin Chorob Wewnetrznych Astmy & Alergii, Lodz, Poland
[3] Uniwersytet Jagiellonki, Katedra Chorob Wewnetrznych 2, Coll Med Krakowie, Krakow, Poland
[4] Inst Gruzlicy & Chorob Pluc Warszawie, Klin Chorob Pluc, Warsaw, Poland
[5] Uniwersytet Med Bialymstoku, Klin Alergol & Chorob Wewnetrznych, Bialystok, Poland
[6] Warszawski Uniwersytet Med, Klin Pneumonol & Alergol Wieku Dzieciecego, Warsaw, Poland
[7] Wojskowy Inst Med Warszawie, Klin Chorob Wewnetrznych Pneumonol & Alergol, Warsaw, Poland
[8] Uniwersytet Med Lodzi, Klin Immunol & Alergii, Lodz, Poland
[9] Slaski Uniwersytet Med, Uniwersyteckie Ctr Klin, Ul Medykow 14, PL-40752 Katowice, Poland
来源：
ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY | 2023年 / 10卷 / 02期
关键词：
severe asthma; immunopathophysiology; biological therapy; efficacy; safety; SEVERE EOSINOPHILIC ASTHMA; TO-SEVERE ASTHMA; DOUBLE-BLIND; OMALIZUMAB; SAFETY; MULTICENTER; MEPOLIZUMAB; BENRALIZUMAB; RISK; REMISSION;
D O I：
10.5114/pja.2023.129093
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Biological therapy represents a breakthrough advance in the treatment of many diseases, including asthma. use of biological drugs, the essence of whose mechanism is a suppressive effect on biologically active proteins determining the phenotypic manifestation of the disease. Data demonstrating the safety and efficacy of biological therapy and the prospects for further development of this area of medicine are presented.
引用
收藏
页码：77 / 99
页数：23
相关论文
共 86 条
  • [1] The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma
    Abraham, B
    Antó, JM
    Barreiro, E
    Bel, EHD
    Bonsignore, G
    Bousquet, J
    Castellsague, J
    Chanez, P
    Cibella, F
    Cuttitta, G
    Dahlén, B
    Dahlén, SE
    Drews, N
    Djukanovic, R
    Fabbri, LM
    Folkerts, G
    Gaga, M
    Gratziou, C
    Guerrera, G
    Holgate, ST
    Howarth, PH
    Johnston, SL
    Kanniess, F
    Kips, JC
    Kerstjens, HAM
    Kumlin, M
    Magnussen, H
    Nijkamp, FP
    Papageorgiou, N
    Papi, A
    Postma, DS
    Pauwels, RA
    Rabe, KF
    Richter, K
    Roldaan, AC
    Romagnoli, M
    Roquet, A
    Sanjuas, C
    Siafakas, NM
    Timens, W
    Tzanakis, N
    Vachier, I
    Vignola, AM
    Watson, L
    Yourgioti, G
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) : 470 - 477
  • [2] Poor control increases the economic cost of asthma - A multicentre population-based study
    Accordini, Simone
    Bugiani, Massimiliano
    Arossa, Walter
    Gerzeli, Simone
    Marinoni, Alessandra
    Olivieri, Mario
    Pirina, Pietro
    Carrozzi, Laura
    Dallari, Rossano
    De Togni, Aldo
    de Marco, Roberto
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 141 (02) : 189 - 198
  • [3] COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence
    Adir, Yochai
    Humbert, Marc
    Saliba, Walid
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (02) : 361 - +
  • [4] Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
    Agache, Ioana
    Beltran, Jessica
    Akdis, Cezmi
    Akdis, Mubeccel
    Canelo-Aybar, Carlos
    Canonica, Giorgio Walter
    Casale, Thomas
    Chivato, Tomas
    Corren, Jonathan
    Del Giacco, Stefano
    Eiwegger, Thomas
    Firinu, Davide
    Gern, James E.
    Hamelmann, Eckard
    Hanania, Nicola
    Makela, Mika
    Martin, Irene Hernandez
    Nair, Parameswaran
    O'Mahony, Liam
    Papadopoulos, Nikolaos G.
    Papi, Alberto
    Park, Hae-Sim
    Perez de Llano, Luis
    Posso, Margarita
    Rocha, Claudio
    Quirce, Santiago
    Sastre, Joaquin
    Shamji, Mohamed
    Song, Yang
    Steiner, Corinna
    Schwarze, Jurgen
    Alonso-Coello, Pablo
    Palomares, Oscar
    Jutel, Marek
    [J]. ALLERGY, 2020, 75 (05) : 1023 - 1042
  • [5] Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases
    Agache, Ioana
    Akdis, Cezmi A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (04) : 1493 - 1503
  • [6] "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis
    Alhossan, Abdulaziz
    Lee, Christopher S.
    MacDonald, Karen
    Abraham, Ivo
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2017, 5 (05) : 1362 - +
  • [7] [Anonymous], XOLAIR LABELLING
  • [8] [Anonymous], 2019, The Diagnosis and Management of Hypertension in the Primary Care Setting Workgroup
  • [9] [Anonymous], NUCALA LABELLING
  • [10] Churg-strauss vasculitis in a patient treated with omalizumab
    Bargagli, Elana
    Madioni, Chiara
    Olivieri, Carmela
    Penza, Francesco
    Rottoli, Paola
    [J]. JOURNAL OF ASTHMA, 2008, 45 (02) : 115 - 116
123456789